PubMed Health⌕ Search

Biomedical subjects

C de la Serna

Publications and source records attributed to C de la Serna.

5 recordsLinked to original sources
PubMed2002

[Acute necrotizing injuries of the upper gastrointestinal tract].

Because of the rich vascular supply and the density of the intramural vascular network in the upper gastrointestinal tract, acute necrotizing injuries at this site are exceptional. However, low-flow states secondary to certain severe systemic diseases can cause ischemic mucosal damage that finally leads to acute local necrosis. Two cases of acute necrotizing lesions in the esophagus and stomach are presented, together with their endoscopic and pathologic characteristics. The pathogenic, clinical and follow-up features of these injuries are also discussed.

Aged↗
PubMed1999

[Helicobacter pylori and digestive hemorrhage due to duodenal ulcer: the prevalence of the infection, the efficacy of 3 triple therapies and the role of eradication in preventing a hemorrhagic recurrence].

BACKGROUND: To report the prevalence of Helicobacter pylori in patients with bleeding duodenal ulcer and to verify the effect of eradication on hemorrhage recurrence. To evaluate the efficacy on H. pylori eradication and on ulcer healing of three one-week triple therapies and to compare their efficacy with that of a dual therapy. PATIENTS AND METHODS: One-hundred and eleven patients with bleeding duodenal ulcer not taking gastroerosive drugs were prospectively studied. At endoscopy, biopsies from gastric antrum and body were obtained (haematoxylin-eosin), and a 13C-urea breath test was also performed. Both diagnostic methods were repeated one month after completing one of the following treatments (randomized study): omeprazole (20 mg/12 h), amoxycillin (1 g/12 h) and clarithromycin (500 mg/12 h) (OAC, n = 27); omeprazole (20 mg/12 h), clarithromycin (500 mg/12 h) and metronidazole (500 mg/12 h) (OCM, n = 27); lansoprazole (30 mg/12 h), amoxycillin (1 g/12 h) and clarithromycin (500 mg/12 h) (LAC, n = 27); and lansoprazole (30 mg/12 h) and clarithromycin (500 mg/8 h) (LC, n = 27). The first three therapies were administered for one week, and LC for two weeks. Once eradication was confirmed no antisecretory therapy was administered. A breath test was performed in the follow-up at 6 months and at one year. RESULTS: The prevalence of H. pylori infection was 97.3% (95% CI: 92-99%). Five patients were lost from the study during follow-up. The eradication efficacy (intention-to-treat) was: OAC, 89% (72-96%); OCM: 93% (77-98%); LAC, 93% (77-98%), and LC, 70% (51-84%). Overall triple therapy efficacy was higher than that of dual therapy (91% vs 70%; p < 0.05). Thirteen patients needed a 2nd or 3rd therapy, and eradication success was finally achieved in all cases. The type of therapy was the only variable which influenced on H. pylori eradication (OR: 4.5; 95% CI: 1.4-14%; p < 0.01) and H. pylori eradication was the only variable which influenced on ulcer healing (OR: 4.7; 95% CI: 1.2-19%; p < 0.05). The yearly reinfection rate was 2.8% (0.9-7.8%). No hemorrhage recurrences occurred during the one year follow-up period. CONCLUSIONS: H. pylori prevalence in bleeding doudenal ulcer is almost 100%. These patients will be spared of hemorrhage recurrence at least for one year if infection is eradicated. Therefore, eradication therapy is the therapy of choice, and maintenance therapy with antisecretory drugs is no longer needed. One-week triple therapies with a proton pump inhibitor and two antibiotics (clarithromycin plus amoxycillin or metronidazole) have a high efficacy in patients with bleeding duodenal ulcer.

Anti-Bacterial Agents↗
PubMed1999

[Acute hepatitis E in Spain].

Hepatitis E virus (HEV) is the worldwide leading cause of non-A non-B enterically transmitted hepatitis, and affects most commonly the population in developing countries. Cases outside this area, are nearly always imported, although apparent local acquisition has been occasionally reported. We assisted three patients with acute HEV hepatitis, confirmed by the presence of serum anti-HEV IgM. One of them did not report travelling outside of Spain in the previous years. HEV has to be included in the differential diagnosis of acute non-A non-B non-C hepatitis, even in cases in which an exposure in endemic areas cannot be recalled.

Acute Disease↗
PubMed1995

[A global study of gastric secretion in duodenal ulcers: gastrin, pepsinogen and acid secretion].

AIM: To examine gastric secretion in duodenal ulcer patients; simultaneous assessment of serum gastrin and pepsinogen I levels and acid secretion. METHODS: 32 patients with duodenal ulcer disease were studied (mean age: 44.7 +/- 14 years, 24 males (75%). At endoscopy, biopsy specimens from duodenal bulb, antrum, body and gastric fundus were taken. Basal levels of acid secretion, pepsinogen I and gastrin were measured, as well as stimulated levels (with pentagastrin and beef meal). RESULTS: Mean (+/- SD) BAO and MAO was 5.5 +/- 4 and 27.7 +/- 10 mEq/h, respectively. BAO in males were higher than in females (p < 0.05). A positive correlation (p < 0.01) was observed between MAO, and basal and stimulated pepsinogen I. Basal and stimulated (integrated-90 min) gastrin levels were 43.4 +/- 12 pg/ml and 5,260 pg/ml min, respectively. No correlation between such levels and acid secretion or pepsinogen I was observed. Mean basal and stimulated (integrated-120 min) pepsinogen levels were 109.3 +/- 35 ng/ml and 4,950 +/- 160 ng/ml min, respectively, and they were higher in males (p < 0.01), and in smokers (p < 0.05). CONCLUSION: It was confirmed, in a group of duodenal ulcer patients, that BAO is higher in males than in females. There is a positive correlation between MAO and pepsinogen I levels, although this correlation is not present between gastrin levels and acid secretion or pepsinogen I. Pepsinogen I levels are higher in males and smokers.

Adult↗